The safety and tolerability of switching from a non-failing antiretroviral regimen to lopinavir

J Infect. 2003 Apr;46(3):204-5. doi: 10.1053/jinf.2002.1114.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Cholesterol / blood
  • Female
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Lopinavir
  • Male
  • Middle Aged
  • Pyrimidinones / therapeutic use*
  • Triglycerides / blood
  • Viral Load

Substances

  • Pyrimidinones
  • Triglycerides
  • Lopinavir
  • Cholesterol